Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Express Scripts
Colorcon
McKinsey
AstraZeneca

Last Updated: September 27, 2022

Pimavanserin tartrate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for pimavanserin tartrate and what is the scope of freedom to operate?

Pimavanserin tartrate is the generic ingredient in one branded drug marketed by Acadia Pharms Inc and is included in two NDAs. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pimavanserin tartrate has one hundred and nineteen patent family members in twenty-three countries.

There are two drug master file entries for pimavanserin tartrate. One supplier is listed for this compound.

Summary for pimavanserin tartrate
Recent Clinical Trials for pimavanserin tartrate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ACADIA Pharmaceuticals Inc.Phase 2
ACADIA Pharmaceuticals Inc.Phase 3
ACADIA Pharmaceuticals Inc.

See all pimavanserin tartrate clinical trials

Pharmacology for pimavanserin tartrate
Anatomical Therapeutic Chemical (ATC) Classes for pimavanserin tartrate
Paragraph IV (Patent) Challenges for PIMAVANSERIN TARTRATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NUPLAZID Tablets pimavanserin tartrate 10 mg 207318 1 2020-04-29
NUPLAZID Capsules pimavanserin tartrate 34 mg 210793 5 2020-04-29

US Patents and Regulatory Information for pimavanserin tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-002 Jun 28, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Acadia Pharms Inc NUPLAZID pimavanserin tartrate CAPSULE;ORAL 210793-001 Jun 28, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for pimavanserin tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-002 Jun 28, 2018 See Plans and Pricing See Plans and Pricing
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-002 Jun 28, 2018 See Plans and Pricing See Plans and Pricing
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-002 Jun 28, 2018 See Plans and Pricing See Plans and Pricing
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for pimavanserin tartrate

Country Patent Number Title Estimated Expiration
Mexico 2007003403 SALES DE N-(4-FLUOROBENCIL) -N-(1-METILPIPERIDIN -4-IL)-N??- (4-(2-METILPROPILOXI) FENILMETIL) CARBAMIDA Y SU PREPARACION. (SALTS OF N-(4-FLUOROBENZYL) -N-(1-METHYLPIPERIDIN -4-YL) -N'-(4-(2- METHYLPROPYLOXY) PHENYLMETHYL) CARBAMIDE AND THEIR PREPARATION.) See Plans and Pricing
Australia 2005289444 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms See Plans and Pricing
Hong Kong 1083759 SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES See Plans and Pricing
European Patent Office 1263729 COMPOSES AZACYCLIQUES UTILISES DANS LE TRAITEMENT DE MALADIES LIEES A LA SEROTONINE (AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Baxter
Johnson and Johnson
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.